| Literature DB >> 35250347 |
Imen Souid1,2, Atef Korchef3, Safouan Souid4.
Abstract
The rapid transmission of the pneumonia (COVID-19) emerged as an entire worldwide health concern and it was declared as pandemic by the World Health Organization (WHO) as a consequence of the increasing reported infections number. COVID-19 disease is caused by the novel SARS-CoV-2 virus, and unfortunatly no drugs are currently approved against this desease. Accordingly, it is of outmost importance to review the possible therapeutic effects of naturally-occuring compounds that showed approved antiviral activities. The molecular docking approach offers a rapid prediction of a possible inhibition of the main enzymes Mpro and RdRp that play crucial role in the SARS-CoV-2 replication and transcription. In the present work, we review the anti-viral activities of polyphenol compounds (phenolic acids, flavonoids and stilbene) derived from the traditional Chinese medicinal Vitis amurensis. Recent molecular docking studies reported the possible binding of these polyphenols on SARS-CoV-2 enzymes Mpro and RdRp active sites and showed interesting inhibitory effects. This antiviral activity was explained by the structure-activity relationships of the studied compounds. Also, pharmacokinetic analysis of the studied molecules is simulated in the present work. Among the studied polyphenol compounds, only five, namely caffeic acid, ferulic acid, quercetin, naringenin and catechin have drug-likeness characteristics. These five polyphenols derived from Vitis amurensis are promising drug candidates for the COVID-19 treatment.Entities:
Keywords: COVID-19; Docking study; Drugs; Polyphenols; Vitis amurensis
Year: 2022 PMID: 35250347 PMCID: PMC8883852 DOI: 10.1016/j.jsps.2022.02.014
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.562
Fig. 1Genomic organization of the Severe Acute Respiratory Syndrome SARS-CoV-2 [created with BioRender.com].
Fig. 2Replication cycle of the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) [created with BioRender.com]. (1) The virus entry to the host cell occurs after the recognition viral spike glycoprotein-ACE2 receptor, resulting in (2) endocytosis and viral genome release in the cytoplasm. (3) Autoproteolysis induces the cleavage of the viral polyproteins by the viral protease Mpro to form nonstructural proteins such as RdRp for the (4) viral RNA replication. The viral RNA (+sense) undergoes translation to form the structural proteins: N, S, E and M. S, E and M are processed in the ER (5) N is processed in the cytoplasm where it brings to the replicon of the viral RNA. (6) All the viral components are combined in the ER-golgi intermediate component (ERGIC) and (7) the formed virions are released inside vesicles then (8) secreted by exocytosis outside the cell.
Fig. 3Amino acid residues involved in forming the active sites for (A) Mpro (PDB ID. 6LU7) and (B) RdRp (PDB ID. 6NUR) [from CASTp server ()]. Letters highlighted in blue color show the active site residues.
Fig. 4Chemical structure of the studied Vitis amurensis polyphenols [molecules are drawn with ChemDraw 20.0]
Antiviral effects of polyphenols derived from Vitis amurensis.
| Compound | Part of the plant | Virus | References |
|---|---|---|---|
| Grape skin | HCoV-NL63 | ||
| Berry | HRVs | ||
| Berry | HCoV-NL63 | ||
| Grape skin | MHV | ||
| Grape skin | HSV | ||
| Root | SARS-CoV | ||
| Berry, leaf | HIV | ||
| Grape skin | IAV(H1N1 and H9N1) | ||
| Berry | SARS-CoV | ||
| Berry | HCV | ||
| Berry, Grape skin | IAV | ||
| Leaf | HSV-1 | ||
| Berry | SARS-CoV | ||
| leaf, stem and root | HCV |
Summary of potential Vitis amurensis polyphenol compounds against SARS-CoV-2 Mpro.
| Compound | Binding energy (Kcal/mol) | Mpro residues interacting with polyphenol compounds through hydrogen bonding and other interactions | References |
|---|---|---|---|
| −4.5 | Leu141, Gly143, SER144, His163,Glu166 | ||
| −8.9 | |||
| −5.7 | Gly143, Ser144, | ||
| −5.4 | Glu14, Met17, Gly71 | ||
| −6.0 | |||
| −8.5 | |||
| −8.5 | |||
| −9.8 | Thr25, Met49, Tyr54, Phe140, Asn142, Gly143, Ser144, His163, Met165, Asp187, Arg188, Gln189 | ||
| −8.9 | |||
| −6.5 | Thr26, | ||
| −7.8 | His163, | ||
| −7.9 | |||
| −7.6 | Thr24, Thr25, Thr26, Leu27, | ||
| −8.4 | Thr26, Met49, Leu141, Gly143, | ||
| −8.4 | Thr24, |
*Mpro catalytic dayd (His41 and Cys145) residues are highlighted with bold font.
1, gallic acid; 2, ellagic acid; 3, caffeic acid; 4, ferulic acid; 5, chlorogenic acid; 6, quercetin; 7, quercetin-3-O-glucuronide: 8, kaempferol-3-O-glucuronide; 9, kaempferol-3-O-rutinoside; 10, myricetin; 11, naringenin; 12, catechin; 13, epigallocatechin gallate; 15, cyanidin-3-O-glucoside; 16, δ-viniferin.
Summary of potential Vitis amurensis polyphenol compounds against SARS-CoV-2 RdRp.
| Compound | Binding energy (Kcal/mol) | RdRp residues interacting with polyphenol compounds through hydrogen bonding and other interactions | Reference |
|---|---|---|---|
| −7.6 | Thr246, Arg249, Ser255, Pro461 | ||
| −7.2 | Asp452, Lys545, Arg553, Ala554, Arg624, Ser682 | ||
| −8.0 | Trp617, Tyr619, | ||
| −7.9 | Trp617, Tyr619, Cys622, | ||
| −9.2 | Trp617, Asp623, | ||
| −7.2 | Trp617, Asp618, Tyr619, Cys622, | ||
| −5.7 | Arg553, Arg555, Thr556, Ser682 | ||
| −5.7 | Lys603, Tyr606, Asp608, Pro612, Leu805, Thr806, Tyr826 | ||
| −9.8 | Tyr456, Arg555, Thr556, Tyr619, Pro620, Lys621, Asp623, Arg624, Thr680, Ser682, Thr687, Ala688, Asn691, | ||
| −8.3 | Ser514, Arg553, Asp616, Asp623, |
*RdRp catalytic residues (Ser759, Asp760 and Asp761) are highlighted with bold font.
2, ellagic acid; 6, quercetin; 7, quercetin-3-O-glucuronide: 8, kaempferol-3-O-glucuronide; 9, kaempferol-3-O-rutinoside; 10, myricetin; 11, naringenin; 13, epigallocatechin gallate; 14, procyanidin B1; 16, δ-viniferin
Prediction of the molecular and drug-likeness proprieties of polyphenols derived from Vitis amurensis.
| Compound | MW | LogP | H-Do | H-Ac | Nrot | TPSA | Mref | LV | GV | VV |
|---|---|---|---|---|---|---|---|---|---|---|
| 170.120 | 0.5016 | 4 | 4 | 1 | 67.135 | 39.470 | 0 | 2 | 0 | |
| 302.190 | 1.1956 | 4 | 8 | 0 | 141.340 | 75.3100 | 0 | 0 | 1 | |
| 180.159 | 1.1960 | 3 | 3 | 2 | 74.381 | 47.160 | 0 | 0 | 0 | |
| 194.186 | 1.4986 | 2 | 3 | 3 | 66.76 | 51.630 | 0 | 0 | 0 | |
| 354.311 | −0.6459 | 6 | 8 | 4 | 141.587 | 83.500 | 1 | 1 | 1 | |
| 302.238 | 1.988 | 5 | 7 | 1 | 122.108 | 78.030 | 0 | 0 | 0 | |
| 478.362 | −0.4466 | 8 | 12 | 4 | 188.063 | 110.770 | 2 | 1 | 1 | |
| 462.363 | −0.1522 | 7 | 11 | 4 | 183.269 | 108.740 | 2 | 0 | 1 | |
| 594.522 | −1.3927 | 9 | 15 | 6 | 236.106 | 139.360 | 3 | 4 | 1 | |
| 318.237 | 1.6936 | 6 | 8 | 1 | 126.902 | 80.060 | 1 | 0 | 1 | |
| 272.256 | 2.5099 | 3 | 5 | 1 | 114.235 | 71.570 | 0 | 0 | 0 | |
| 290.271 | 1.5461 | 5 | 6 | 1 | 119.662 | 74.330 | 0 | 0 | 0 | |
| 458.375 | 2.2332 | 8 | 11 | 3 | 184.742 | 112.060 | 2 | 0 | 1 | |
| 578.526 | 2.995 | 10 | 12 | 3 | 236.950 | 183.510 | 3 | 2 | 1 | |
| 449.388 | 0.3820 | 8 | 10 | 4 | 179.740 | 108.290 | 2 | 0 | 1 | |
| 454.478 | 5.6506 | 5 | 6 | 4 | 195.452 | 130.240 | 0 | 1 | 0 |
MW, molecular weight (g/mol); LogP , predicted octanol/water partition coefficient; H-Do, hydrogen bond donors; H-Ac, hydrogen bond acceptors; Nrot, number of rotatable bonds; TPSA, topological polar surface area (A2); Mref, Molar refractivity , LV, Lipinski violation; GV, Ghose violation; VV, Veber violation, 1, gallic acid; 2, ellagic acid; 3, caffeic acid; 4, ferulic acid; 5, chlorogenic acid; 6, quercetin; 7, quercetin-3-O-glucuronide: 8, kaempferol-3-O-glucuronide; 9, kaempferol-3-O-rutinoside; 10, myricetin; 11, naringenin; 12, catechin; 13, epigallocatechin gallate; 14, procyanidin B1; 15, cyanidin-3-O-glucoside; 16, δ-viniferin
SwissADME pharmacokinetics prediction for polyphenols derived from Vitis amurensis.
| Compound | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absorption | ||||||||||||||||
| WS | −1.914 | −3.181 | −2.330 | −2.909 | −2.449 | −2.925 | −2.897 | −2.866 | −2.900 | −2.915 | −3.224 | −3.117 | −2.894 | −2.892 | −2.929 | −2.962 |
| Caco2 permeability | −0.026 | 0.335 | 0.634 | 0.195 | −0.840 | −0.229 | −1.061 | −0.884 | 0.189 | 0.095 | 1.029 | −0.283 | −1.521 | −1.225 | 0.058 | −0.989 |
| HIA | 40.154 | 86.684 | 69.407 | 93.220 | 36.377 | 77.207 | 25.112 | 25.165 | 30.743 | 65.930 | 91.310 | 68.829 | 47.395 | 66.749 | 45.392 | 87.907 |
| Skin permeability | −2.737 | −2.735 | −2.722 | −2.722 | −2.735 | −2.735 | −2.735 | −2.735 | −2.735 | −2.735 | −2.742 | −2.735 | −2.735 | −2.735 | −2.735 | −2.735 |
| P-gp substrate | No | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| P-gpI inhibitor | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | Yes |
| P-gpII inhibitor | No | No | No | No | No | No | No | No | No | No | No | No | Yes | Yes | No | Yes |
| Distribution | ||||||||||||||||
| VDss | −0.270 | 0.375 | −1.098 | −1.098 | 0.581 | 1.559 | 1.647 | 1.295 | 1.710 | 1.317 | −0.015 | 1.027 | 0.806 | −0.158 | 1.464 | −2.013 |
| BBB permeability | −1.424 | −1.272 | −0.647 | −0.280 | −1.407 | −1.098 | −1.614 | −1.441 | −1.669 | −1.493 | −0.578 | −1.054 | −2.184 | −1.940 | −1.713 | −1.188 |
| CNS permeability | −4.131 | −3.533 | −2.608 | −2.535 | −3.856 | −3.065 | −4.139 | −3.955 | −5.015 | −3.709 | −2.215 | −3.298 | −3.96 | −3.983 | −3.813 | −2.837 |
| Metabolism | ||||||||||||||||
| CYP2D6 substrate) | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| CYP3A4 substrate | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes |
| CYP1A2 inhibitor | No | Yes | No | No | No | Yes | No | No | No | Yes | Yes | No | No | No | No | No |
| CYP2C19 inhibitor | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes |
| CYP2C9 inhibitor | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes |
| CYP2D6 inhibitor | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| CYP3A4 inhibitor | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No | No |
| Excretion | ||||||||||||||||
| Total Clearance | 0.625 | 0.537 | 0.508 | 0.619 | 0.307 | 0.407 | 0.434 | 0.503 | −0.160 | 0.422 | 0.060 | 0.183 | 0.292 | −0.085 | 0.522 | −0.101 |
| Renal OCT2 substrate | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No |
| Toxicity | ||||||||||||||||
| AMES toxicity | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Max. Tolerated dose | 0.519 | 0.476 | 1.145 | 1.444 | −0.134 | 0.499 | 0.427 | 0.460 | 0.481 | 0.510 | −0.176 | 0.438 | 0.441 | 0.438 | 0.562 | 0.408 |
| hERGI inhibitor | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| hERGII inhibitor | No | No | No | No | No | No | No | No | Yes | No | No | No | Yes | Yes | Yes | Yes |
| LD50 | 2.03 | 2.399 | 2.383 | 2.322 | 1.973 | 2.471 | 2.497 | 2.513 | 2.513 | 2.497 | 1.791 | 2.428 | 2.522 | 2.482 | 2.549 | 2.606 |
| LOAEL | 3.241 | 2.698 | 2.092 | 1.794 | 2.982 | 2.612 | 4.510 | 4.641 | 3.569 | 2.718 | 1.944 | 2.5 | 3.065 | 4.349 | 4.201 | 3.309 |
| Hepatotoxicity | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Skin sensitization | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Minnow toxicity | 1.938 | 2.110 | 2.246 | 2.074 | 5.741 | 3.721 | 8.323 | 6.898 | 6.252 | 5.023 | 2.136 | 3.585 | 7.713 | 8.704 | 6.398 | 0.503 |
WS, Water solubility (log mol/L); Caco2 permeability (log Papp in 10-6 cm/s); HIA, Human intestinal absorption (% Absorbed); Skin permeability (log Kp); P-gp substrate, P-glycoprotein substrate; P-gpI inhibitor, P-glycoprotein I inhibitor, P-gpII inhibitor, P-glycoprotein II inhibitor, VDss, volume of distribution in human body (log L/Kg); BBB permeability (log BB); CNS permeability (log PS); Total Clearance (log ml/min/Kg); Max. Tolerated dose (human) (log mg/Kg/day); LD50, Oral Rat Acute Toxicity (mol/Kg); LOAEL, Oral Rat Chronic Toxicity (log mg/Kg_bw/day); Minnow toxicity (log mM); 1, gallic acid; 2, ellagic acid; 3, caffeic acid; 4, ferulic acid; 5, chlorogenic acid; 6, quercetin; 7, quercetin-3-O-glucuronide: 8, kaempferol-3-O-glucuronide; 9, kaempferol-3-O-rutinoside; 10, myricetin; 11, naringenin; 12, catechin; 13, epigallocatechin gallate; 14, procyanidin B1; 15, cyanidin-3-O-glucoside; 16, δ-viniferin
Fig. 5Schematic representation of the SARS-CoV-2 protease inhibitory effects of some Vitis amurensis polyphenols selected according to their drug-likeness characteristics [created with BioRender.com]